Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report) shares saw strong trading volume on Monday. 1,462,601 shares were traded during mid-day trading, an increase of 27% from the average daily volume of 1,147,313 shares. The stock last traded at $5.7950 and had previously closed at $6.31.
Analysts Set New Price Targets
Several research firms have recently issued reports on AVR. Barclays upgraded Anteris Technologies Global to a "hold" rating in a report on Wednesday, October 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 price target on shares of Anteris Technologies Global in a research note on Wednesday, October 14th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $14.00.
Check Out Our Latest Stock Report on AVR
Anteris Technologies Global Stock Performance
The stock's fifty day moving average is $7.56 and its two-hundred day moving average is $7.37. The firm has a market cap of $574.04 million, a price-to-earnings ratio of -3.02 and a beta of 2.02.
Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period last year, the company earned ($0.58) earnings per share. Sell-side analysts predict that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.
Insider Transactions at Anteris Technologies Global
In other news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the business's stock in a transaction dated Monday, October 5th. The stock was acquired at an average price of $7.51 per share, for a total transaction of $4,869,897.05. Following the completion of the acquisition, the insider directly owned 12,778,380 shares in the company, valued at $95,965,633.80. This represents a 5.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders acquired 1,554,730 shares of company stock worth $11,694,513 and sold 1,305,369 shares worth $11,380,022. Insiders own 4.50% of the company's stock.
Institutional Trading of Anteris Technologies Global
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $56,846,000. Nantahala Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $33,325,850. ADAR1 Capital Management LLC bought a new position in Anteris Technologies Global during the second quarter valued at approximately $30,979,000. Perceptive Advisors LLC lifted its stake in shares of Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company's stock valued at $19,011,000 after purchasing an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC acquired a new position in shares of Anteris Technologies Global during the 1st quarter valued at about $3,663,000.
Anteris Technologies Global Company Profile
(
Get Free Report)
Anteris Technologies Global is a medical device company focused on developing structural heart products for the treatment of heart valve disease. Its primary focus is transcatheter aortic valve replacement (TAVR), a minimally invasive procedure used to replace a diseased aortic valve without traditional open-heart surgery.
The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the function and hemodynamic performance of a healthy human aortic valve.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anteris Technologies Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anteris Technologies Global wasn't on the list.
While Anteris Technologies Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.